Sarah leads IFPMA’s regulatory workstream on Biotherapeutic and Advanced Therapies at the international level. She is also responsible for overseeing regulatory policy and advocacy activities in Africa and beyond.
This includes engagement with various key global stakeholders and regional organizations involved in regulatory harmonization and system strengthening to improve access to medicinal products to benefit patients.
Previously, Sarah worked in regulatory and scientific affairs at the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).
Working in academia, Sarah spent more than 10 years researching into pulmonary and pancreatic disease preclinical drug testing and vaccine development. Sarah was an appointed lecturer at the School of Pharmacy at the University of Geneva. She holds a PhD degree in Molecular Biology and an Engineering degree in Biotechnology.
Collaborations and partnerships like those supported by IFPMA are crucial. Whatever link you have in the chain enables the changes and advancements needed to accelerate access to medicinal products for patients worldwide.
More from Sarah
Ways to strengthen the clinical research ecosystem in resource-limited settings
Encouraging clinical research in low-income settings is essential to tap into opportunities that can make a difference in patients’ lives. Sarah Adam, Associate Director, Regulatory Affairs at IFPMA, shares perspectives on key pillars to support this.
Read more
How the COVID-19 pandemic sparked innovation in clinical trials: considerations for the future
The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Sarah Adam explains what we can learn from this experience when it comes to clinical trials.
Read more